Why the study?
Do drug price reductions and prescribing restrictions reduce expenditures and utilization of antihypertensive drugs in patients with primary hypertension?
Population
54,295 participants with primary hypertension from the National patient sample data of Health Insurance…
Comparison
Drug price reduction policy and new guidelines… vs Before policy implementation (March 2012)
Design
Cohort
Follow-up
March 2011 to December 2013
Key result
Drug price reduction and new prescribing guidelines reduced antihypertensive drug expenditures by 10.2% and 16.2% respectively, saving US$4.22 per patient.
Authors
Loading...
Price and guideline policies were associated with savings; leaves open effects on adherence and outcomes.
Observational (n=54,295)
Yes
Do drug price reductions and prescribing restrictions reduce expenditures and utilization of antihypertensive drugs in patients with primary hypertension?
Drug price reduction policies and prescribing restriction guidelines effectively reduced antihypertensive drug expenditures and utilization in South Korea.
Yoo et al. (2015) conducted an observational in primary hypertension (n=54,295). Drug price reduction and prescribing restrictions vs. Before policy implementation was evaluated on antihypertensive drug costs. Drug price reduction and new prescribing guidelines reduced antihypertensive drug expenditures by 10.2% and 16.2% respectively, saving US$4.22 per patient.